<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811629</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0042</org_study_id>
    <nct_id>NCT00811629</nct_id>
  </id_info>
  <brief_title>Influence of Acute Respiratory Distress Syndrome (ARDS) and Severe Sepsis on sRAGE Levels in ICU Patients</brief_title>
  <official_title>Soluble Form of the Receptor for Advanced Glycation End Products (sRAGE) Levels in the Pulmonary Edema Fluid and Plasma From ICU Patients With ALI/ARDS and Severe Sepsis : an Observational Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      sRAGE, the soluble form of the receptor for advanced glycation end products, is a novel&#xD;
      marker of alveolar epithelial type I cell injury, but is also involved in acute systemic&#xD;
      inflammation. The purpose of this observational prospective study is to determine whether&#xD;
      sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during&#xD;
      ALI/ARDS, regardless of associated severe sepsis or septic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      The receptor for advanced glycation end products (RAGE was recently identified as a promising&#xD;
      new marker of alveolar type I cell injury. RAGE is a member of the immunoglobulin superfamily&#xD;
      that acts as a multiligand receptor and is involved in propagating inflammatory responses.&#xD;
      While the precise function of RAGE remains unclear, the elevated levels of RAGE, and its&#xD;
      soluble isoform sRAGE, correlate with severity of ALI/ARDS in human and animal studies, and&#xD;
      RAGE levels could reflect impaired alveolar fluid clearance. Thus, it is possible that&#xD;
      elevated levels of RAGE in ALI/ARDS derive in part from RAGE's role in systemic inflammatory&#xD;
      cascades rather than purely from its release from alveolar type I cells.&#xD;
&#xD;
      DESIGN NARRATIVE:&#xD;
&#xD;
      This observational prospective clinical study will describe and compare sRAGE levels in the&#xD;
      alveolar edema fluid and in the plasma from ICU patients enrolled within the first 24 hours&#xD;
      after onset of ALI/ARDS and/or severe sepsis/septic shock, and from patients under mechanical&#xD;
      ventilation (control group). Edema fluid and plasma samples will be collected simultaneously&#xD;
      on day 1, day 3, day 6, and day 28 (or at ICU discharge), in order to describe kinetics of&#xD;
      evolution of sRAGE levels. Undiluted pulmonary edema fluid samples will be collected in&#xD;
      intubated patients only, and blood samples will be gathered from an indwelling arterial&#xD;
      catheter. The concentrations of sRAGE will be measured in duplicate by ELISA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sRAGE levels in the plasma from ICU patients within the first 24 hours after onset of ALI/ARDS or severe sepsis/septic shock</measure>
    <time_frame>within the first 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe kinetics of evolution of sRAGE levels in ICU patients with ALI/ARDS and severe sepsis/septic shock</measure>
    <time_frame>in UCU patients</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Lung Injury</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Mechanical Ventilation</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sRAGE</intervention_name>
    <description>The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Definied population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ICU patients under mechanical ventilation&#xD;
&#xD;
          -  Patients within the first 24 hours after onset of ALI/ARDS according to the 1994&#xD;
             American-European Consensus Conference (AECC)&#xD;
&#xD;
          -  Patients within the first 24 hours after onset of severe sepsis or septic shock&#xD;
             according to the 1992 ACCP/SCCM Consensus Conference&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Acute exacerbation of diabetes&#xD;
&#xD;
          -  Dialysis for end-stage kidney disease&#xD;
&#xD;
          -  Alzheimer's disease&#xD;
&#xD;
          -  Amyloidosis&#xD;
&#xD;
          -  Evolutive neoplastic lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu JABAUDON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Receptor for advanced glycation end products (RAGE)</keyword>
  <keyword>Soluble RAGE (sRAGE)</keyword>
  <keyword>Acute Lung Injury (ALI)</keyword>
  <keyword>Acute respiratory distress syndrome (ARDS)</keyword>
  <keyword>Severe sepsis</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Alveolar epithelium</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Intensive Care Unit (ICU)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

